Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 9-THC; Delta9-Tetrahydrocannabinol; Deltanyne; Dronabinol inhaled; Elevat; Marinol; NSC-134454; Pulmonary dronabinol - Solvay/Nektar Therapeutics; δ9-tetrahydrobannabinol

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unimed Pharmaceuticals
  • Developer Nektar Therapeutics; Unimed Pharmaceuticals
  • Class Antidementias; Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anorexia nervosa; Nausea and vomiting
  • Discontinued Migraine

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2005 Phase-II clinical trials in Migraine (Inhalation)
  • 20 May 2005 Data from a media release have been added to the Advances in the Treatment of Nausea and Migraine therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top